These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6805621)

  • 21. Once daily beta-blocker in hypertension--oxprenolol slow-release.
    Gordon RD; Ziesak M; Rowe WS; Strakosch CR; Row G
    J Int Med Res; 1981; 9(1):6-11. PubMed ID: 7009256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with once-daily and twice-daily slow-release frusemide in hypertension.
    Vadász TA; Chadha DR
    J Int Med Res; 1982; 10(4):199-203. PubMed ID: 7117676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of once and twice daily administration of acebutolol in hypertension.
    Watson RD; Stallard TJ; Littler WA
    Br J Clin Pharmacol; 1980 Feb; 9(2):209-12. PubMed ID: 6766731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of alprenolol in combination with hydralazine in essential hypertension. A double-blind, crossover study and a long-term follow-up study.
    Pape J
    Acta Med Scand Suppl; 1974; 554():55-62. PubMed ID: 4593674
    [No Abstract]   [Full Text] [Related]  

  • 25. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
    Ravid M; Lang R; Jutrin I
    Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isradipine: a slow-release formulation given once daily controls blood pressure for 24 h.
    Holmes DG
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):74S-76S. PubMed ID: 8466733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of nifedipine in the treatment of resistant hypertension. Comparison with hydralazine in hospital outpatients.
    Murphy MB; Bulpitt CJ; Dollery CT
    Am J Med; 1984 Aug; 77(2B):16-21. PubMed ID: 6486124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension.
    Hedner T; Elmfeldt D; Dahlöf C; Sjögren E
    Drugs; 1987; 34 Suppl 3():125-31. PubMed ID: 3443058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of once and twice daily atenolol in hypertension.
    Castleden CM; Dathan JR; George CF
    Postgrad Med J; 1977 Nov; 53(625):679-82. PubMed ID: 339214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single versus multiple daily administration of hydralazine in the maintenance treatment of hypertension. Clinical and pharmacokinetic aspects.
    Henningsen NC; Hanson A; Wernersson B
    Acta Med Scand; 1982 May; 211(3):179-85. PubMed ID: 7044051
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of felodipine in the treatment of severe hypertension.
    Muir AL; Wathen CG
    Drugs; 1987; 34 Suppl 3():120-4. PubMed ID: 3327673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.
    Ramsay LE; Parnell L; Waller PC
    Postgrad Med J; 1987 Feb; 63(736):99-103. PubMed ID: 3671250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reserpine, hydralazine, hydrochlorothiazide combination (Ser-AP-ES) in essential hypertension.
    Glazer N
    Curr Ther Res Clin Exp; 1972 Sep; 14(9):561-72. PubMed ID: 4628678
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone.
    Kieso HA; Gould BA; Mann S; Hornung RS; Altman DG; Raftery EB
    Br Med J (Clin Res Ed); 1983 Sep; 287(6394):717-20. PubMed ID: 6412795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):91-3. PubMed ID: 786690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypotensive action of verapamil in a group of hydralazine-dependent hypertensive patients.
    González-Gómez A; Gamio-Capestany F; García-Barreto D
    Arch Int Pharmacodyn Ther; 1983 Feb; 261(2):268-77. PubMed ID: 6838286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
    Carlsen JE; Jensen HA; Rehling M; Lund JO; Trap-Jensen J
    Drugs; 1988; 36 Suppl 7():55-63. PubMed ID: 3076136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 40. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.